Published Ahead of Print on March 3, 2021 as 10.1212/WNL.0000000000011760

Neurology®
The most widely read and highly cited peer-reviewed neurology journal
The Official Journal of the American Academy of Neurology

AMERICAN ACADEMY OF NEUROLOGY®

Neurology Publish Ahead of Print
DOI: 10.1212/WNL.0000000000011760

Resident & Fellow Section

Journal Club: Trends in Incidence and Epidemiological Characteristics of Cerebral Venous Thrombosis in the United States

Nikolaos Raptis[1], MD; Susanna M Zuurbier[2], MD, PhD; Mirjam R Heldner[1], MD, MSc

[1]Department of Neurology, Inselspital, University Hospital and University of Bern, Bern, Switzerland

[2]Department of Neurology, Antwerp University Hospital and University of Antwerp, Antwerp, Belgium

Correspondence

Mirjam R Heldne

mirjam.heldner@insel.ch

Title character count: 93

Number of tables: 0

Number of figures: 0

Word count: 1829

Search terms: cerebral venous thrombosis, incidence

Study Funding

No targeted funding reported.

Disclosure

The authors report no disclosures relevant to the manuscript.

Acknowledgments

We thank Susan E. Kaplan for proofreading our manuscript.

Introduction

Cerebral venous thrombosis (CVT) is rare. Early estimations of its incidence were derived from autopsy series and were extrapolated to be around 0.1 to 0.2 patients

with CVT per 100,000 per year.[1] Recently, a cross-sectional study in the Netherlands and a population-based study in Australia, found a much higher incidence of up to 1.6 per 100,000 per year.[2,3] Even higher incidences have been reported in the Middle East.[4] Wider availability of imaging, technological advances, and a shift in risk factors might explain these differences.[2,3,4]

This Journal Club article reports on a large retrospective cohort study by Otite et al.[5] conducted in the United States (US), which confirmed the trend towards an increased incidence of CVT. The authors also shed light on age-, sex-, and race-specific incidence of CVT, and risk factor profiles of CVT patients in a multi-ethnic population. A clear understanding of the epidemiological characteristics of CVT has important implications for public health.

Hypothesis and design

The authors hypothesized that race-, age-, and sex-specific incidence of CVT has increased in the US over the past decade. Given the lack of recent data on dynamics of demographic and risk factor profiles in multi-ethnic populations,[5,6] the authors' primary aims were a) to determine the current age-, sex-, and race-specific incidence of CVT in the US, b) to investigate trends in incidence and overall burden of CVT hospitalizations in the US, and c) to describe trends in the prevalence of CVT risk factors in the US over the past decade.

They conducted a large retrospective cohort study using the State Inpatients Database (SID) of New York and Florida, and the National Inpatient Sample (NIS) database in the US.

Methods

Case identification for incident CVT hospitalizations

The authors used administrative claims data from acute care hospitals contained in the SID of Florida and New York – which covered up to 97% of US community hospital discharges – to identify patients with first-ever CVT between 2006 and 2016. Florida and New York are home to >10% of the total US population and are also demographically diverse.

National burden of CVT hospitalizations

To ensure generalizability of the results to the entire US, data on national trends in the burden of CVT hospitalizations and the epidemiological characteristics of CVT were acquired from the NIS database, which comprises a 20% stratified sample of all US hospital discharges.

US population data

Data on age, sex, and race were obtained from the US Census Bureau website.

Outcome identification

A first-ever CVT was defined as the first hospitalization incorporating a corresponding International Classification of Diseases (ICD-9/10) code. A one-year washout period (2005) was applied to minimize the influence of earlier CVT hospitalizations on study estimates after this year. Relevant risk factors for CVT were defined as already established in the literature and were identified by the Health Care Utilization Project software or the ICD-9/10 codes. Age was stratified according to

the following age groups: 18-44, 45-64, and ≥65 years of age. The nature of the dataset allowed the sex categories of men and women and the racial categories of Non-Hispanic Whites, Non-Hispanic Blacks, African Americans, Hispanics, and Asians to be differentiated.

Statistical analysis

Descriptive statistics were used to calculate the annual incidence of CVT in the two states studied. Age-stratified and crude estimates by sex and race were also obtained. Similarly, the annual incidence of CVT in the whole US and in both sex groups was calculated. Joinpoint regression models were applied in this study to assess the trends in the incidence of CVT and in the burden of CVT hospitalizations over time. Joinpoint regression is a well-known approach used to study potential changes in trends over time that might happen following interventions or changes in external conditions. It can identify if/when changes in population parameters occur. Time and population parameters are inputted into the model. For example, it has been applied for analysis of cancer or motor vehicle collision mortality rates and of disease risk. A logistic regression model was used to identify a possible linear trend in the prevalence of each CVT risk factor over time. Each risk factor was used as the dependent variable and the year of discharge as the independent variable, evaluated continuously, with the significance of differences in trend over time assessed using the Wald test. Regression analysis is a statistical technique for estimating the relationships among variables.

Results

Between 2005 and 2016 there were 57,315 weighted admissions of CVT patients in the entire US, representing 0.66% of all adult hospitalizations for any cerebrovascular

disease within this period. A cohort of 5,567 CVT patients was identified. About two-thirds of all patients hospitalized with CVT in the entire US were women, but this proportion declined over time, while the proportion of hospitalizations of men increased by 88.6% over time (p-trend <0.001). The mean age of women with CVT steadily increased during the study period (p-trend <0.001). Over time, the proportion of young women affected by CVT declined significantly, while the proportion of all other age groups affected increased. The combined proportions (women and men) of elderly patients hospitalized with CVT more than doubled during the study period from 11.2% to over 24%. The age and sex distribution of CVT patients in the states of Florida and New York were very similar to that of the entire US.

Regarding CVT risk factors, the proportion of hospitalizations of women during pregnancy and puerperium decreased by over 50% over time in the US as a whole but remained the most frequent risk factor for CVT. The proportion of hospitalizations of patients with comorbid cancer and central nervous system trauma increased significantly over time in both sexes (all p-trends <0.001). The findings for the states of Florida and New York were again very similar to that of the entire US.

Annual age- and sex-standardized incidence of CVT in the two selected states in cases/million population ranged from 13.9 to 20.2, but incidence was significantly higher in women. The incidence of CVT increased over the study period, but the rate of increase was 4-fold more rapid in men and increased in all age groups. The increase in incidence in women was driven by middle-aged and elderly women. The sex ratio in elderly CVT patients was evenly distributed. The national burden of

hospitalizations of patients with CVT increased consistently throughout the study period. Incidence also differed by race (Blacks > Whites > Asians).

A sensitivity analysis restricted to the period from 2006 to 2014 did not lead to any relevant differences in the findings.

Interpretation

The study by Otite et al.[5] has contributed to the literature by describing the current incidence of CVT in the US and highlighting demographic changes in this disease.

The strengths of this study are the population-based dataset with details on ethnic background and the large sample size, which allowed for meaningful subgroup analyses. In addition, the authors provided national estimates of the burden of risk factors.

The main limitation of the study is the potential underdetection/-estimation bias. Several aspects of the study could contribute to this potential bias. First, patients with asymptomatic or mild CVT were probably not hospitalized. Second, codes used for CVT diagnosis have only modest sensitivity. Third, a small proportion of patients may have been misdiagnosed when they initially presented at the emergency room. Also, cumulative incidence calculations assumed a closed population, which may have contributed not only to potential under- but also to overdetection/-estimation. A further contribution to overdetection/-estimation is possible from patients who were counted more than once or who were hospitalized for non-CVT related illness.

Moreover, hospitalizations with missing tracking variables as well as missing information on age and/or sex, and patients who were non-residents of the state in which they were hospitalized have been excluded. This bias might decrease the validity of the study. Finally, the generalizability of the data to the whole US is somewhat limited, since the CVT population selected represents a selection bias.

This study used claims data, which raises the following concerns: that healthcare providers might up-code diagnoses in claims, that claims data consist of standardized but non-homogeneous information, that duration of follow-up is usually restricted, and that validation studies concerning claims are scarce. Major benefits of claims data include the review of a large number of patients treated by different healthcare providers and their high external validity, as there is no reimbursement without submitting data.

Based on the literature, we would have expected oral contraceptive use to be a far greater CVT risk factor and this raises the question of whether it was underreported in this cohort.[7,8] Furthermore, the formulations of oral contraceptives used likely varied among the population under study and over time. Additionally, transgender male to female individuals taking oral contraceptives were probably neglected in the population analyzed. Also, hormone replacement therapy is a well-known risk factor for CVT but was not identified as such in this study.[8] An increase in intake of hormone replacement therapy in middle-aged and elderly women might partially explain the increase in incidence of CVT in those women over time.
Changes in prevalence of known CVT risk factors, like the increased number of traumas of the central nervous system and emerging or unknown CVT risk factors,

might help to explain the disproportionate increase in the pace of CVT detection over time in men.

Compared to European data, arterial hypertension and diabetes mellitus were found more often in this cohort, which might reflect the higher prevalence of these vascular risk factors in the US population.[8,9]

Information on hypercoagulable disorders in the study patients, e.g., Factor V Leiden or prothrombin gene mutation, was not available although thrombophilia is one of the most common CVT risk factors.[8]

Thus, there might have been both under- and over-ascertainment bias concerning risk factors.

The analysis of trends was based on the implicit assumption of unchanged coding practices over time but the study period overlapped with the changeover from ICD-9 to ICD-10 utilization. ICD-10 goes along with higher positive predictive values of CVT.[10]

Whether the overall increase in CVT incidence seen in this study constitutes a true increase resulting from changing risk factors or an artifactual increase resulting from better detection, remains an open question even though the authors provided some explanations supporting the first hypothesis. Importantly, the improvement, not only in radiological but also in clinical detection, may have occurred disproportionally in different demographic groups over time. Overall, more women were affected by CVT than men, but these differences were not seen in elderly patients in this cohort, which is in line with previous findings.[7]

The study has made an important contribution to this field of cerebrovascular diseases and has highlighted the changing trends in demographic characteristics of patients with CVT. Its crucial findings were the doubling of the incidence of CVT hospitalizations in the elderly and the increased age- and sex-standardized incidence of CVT in Blacks.

Inequity plays an important role in cerebrovascular health and should be a focus in future cohort studies as well as prospective multi-ethnic studies in this field.

Appendix 1: Authors

Name	Location	Contribution
Nikolaos Raptis, MD	Inselspital, University Hospital and University of Bern, Bern, Switzerland	drafting/revising the manuscript, analysis or interpretation of data, accepts responsibility for conduct of research and final approval
Susanna M. Zuurbier, MD, PhD	Antwerp University Hospital and University of Antwerp, Antwerp, Belgium	drafting/revising the manuscript, analysis or interpretation of data, accepts responsibility for conduct of research and final approval
Mirjam R. Heldner, MD, MSc	Inselspital, University Hospital and University of Bern, Bern, Switzerland	drafting/revising the manuscript, analysis or interpretation of data, accepts responsibility for conduct of research and final approval

References

1. Stam J. Cerebral venous thrombosis and sinus thrombosis: incidence and causes. Adv Neurol. 2003;92:225-232.

2. Coutinho JM, Zuurbier SM, Aramideh M, Stam J. The incidence of cerebral venous thrombosis: a cross-sectional study. Stroke. 2012;43:3375-3377.

3. Devasagayam S, Wyatt B, Leyden J, Kleinig T. Cerebral venous sinus thrombosis incidence is higher than previously thought: a retrospective population-based study. Stroke. 2016;47:2180-2182.

4. Janghorbani M, Zare M, Saadatnia M, Mousavi SA, Mojarrad M, Asgari E. Cerebral vein and dural sinus thrombosis in adults in Isfahan, Iran: frequency and seasonal variation. Acta Neurol Scand. 2008;117:117-121.

5. Otite FO, Patel S, Sharma R, et al. Trends in incidence and epidemiological characteristics of cerebral venous thrombosis in the United States. Neurology Epub 2020 August 26.

6. Field TS, Hill MD. Cerebral venous thrombosis: we should ask the right questions to get better answers. Stroke 2019;50:1598-1604.

7. Zuurbier SM, Middeldorp S, Stam J, Coutinho JM. Sex differences in cerebral venous thrombosis: A systematic analysis of shift over time. Int J Stroke. 2016;11:164-170.

8. Ferro JM, Canhão P, Stam J, Bousser MG, Barinagarrementeria F; ISCVT Investigators. Prognosis of cerebral vein and dural sinus thrombosis: results of the

International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke. 2004;35:664-670.

9. Zuurbier SM, Hiltunen S, Tatlisumak T, et al. Admission hyperglycemia and clinical outcome in cerebral venous thrombosis. Stroke. 2016;47:390-396.

10. Handley JD, Emsley HC. Validation of ICD-10 codes shows intracranial venous thrombosis incidence to be higher than previously reported. Health Inf Manag. 2020;49:58-61.

Journal Club: Trends in Incidence and Epidemiological Characteristics of Cerebral Venous Thrombosis in the United States

Nikolaos Raptis, Susanna M Zuurbier and Mirjam R Heldner

Neurology published online March 3, 2021
DOI 10.1212/WNL.0000000000011760